The $20M milestone payment confirms clinical progress in the Takeda partnership, but the $5M buyback is trivial relative to market cap. Traders should focus on upcoming elritercept data readouts and rinvatercept trial milestones as the next catalysts. Cash runway into H2 2028 reduces near-term dilution risk.
Price Chart
Executive Summary
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone payment from Takeda for elritercept (ELRiSE MDS trial first patient dosed). The company had $257.6 million in cash as of June 30, 2026, and expects cash runway into the second half of 2028. The modest buyback signals capital return but is not transformative given the clinical-stage status and limited program progress.
Key Facts
- $5 million share repurchase authorized
- $20 million milestone payment from Takeda for elritercept (ELRiSE MDS trial first patient dosed)
- Cash and cash equivalents of $257.6 million as of June 30, 2026
- Cash runway expected into second half of 2028 after milestone and buyback
Financial Impact
$5M buyback vs $221M market cap (~2.3%); $20M milestone adds to existing $257.6M cash; net cash impact ~+$15M
Risk Factors
- Clinical trial failure or delay (elritercept, rinvatercept)
- Pre-revenue stage with no approved products
- Buyback may be modified, suspended, or discontinued at any time
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000053 |
| Exhibit: exhibit9919826pr.htm | 0001664710-26-000053 |
| Document: 0001664710-26-000053-index-headers.html | 0001664710-26-000053 |
| Document: 0001664710-26-000053-index.html | 0001664710-26-000053 |
| Document: 0001664710-26-000053.txt | 0001664710-26-000053 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 23d ago | 8-K | $11.31 $11.04 | ▼ −2.39% | ▼ −2.05% | $11.17 (−1.24%) |
Aug 20, 2026 6w ago | Insider Cluster | $10.95 $11.23 | ▲ +2.56% | ▲ +1.44% | $11.17 (+2.01%) |
Aug 3, 2026 8w ago | 8-K | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Aug 3, 2026 8w ago | Press Release | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Jul 30, 2026 9w ago | 8-K | $10.07 $11.15 | ▲ +10.72% | ▲ +7.21% | $11.17 (+10.92%) |
Jul 22, 2026 10w ago | 8-K | $10.14 $10.22 | ▲ +0.79% | ▲ +0.31% | $11.17 (+10.16%) |
Jun 17, 2026 15w ago | Insider Cluster | $10.65 $10.41 | ▼ −2.25% | ▼ −0.59% | $11.17 (+4.88%) |
Jun 8, 2026 16w ago | Insider Cluster | $10.07 $10.24 | ▲ +1.69% | ▼ −0.72% | $11.17 (+10.92%) |
May 14, 2026 20w ago | 8-K | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
May 14, 2026 20w ago | Press Release | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access